Clinical trials: Regression
Secondary Hyperparathyroidism, End Stage Renal Disease
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
- Trial name
- NCT00053547
- Testing
- paricalcitol injection
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Abbott
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02900664
- Testing
- PDR001, ACZ885, CJM112
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Post Operative Pain, Cesarean Section Pain
Application of Transversus Abdominus Plain Block, Local Subcutaneous Injection and IV Nalbuphine
Approximately 1 in 5 women who undergo CS will experience severe acute postoperative pain. The severity of pain in the acute postoperative period is a significant predictor for the development of chronic pain, which occurs in…
- Trial name
- NCT05276206
- Testing
- NSAID , NALUFIN , local anesthetic andTAP Block
- Where
- Egypt
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Procedural Pain
Comparing Buzzy Device With Emla Cream in Needle Related Pain
This randomized controlled study will enroll the eligible patients to either the Buzzy device arm or to the EMLA cream arm as a standard therapy. This will be done with concealment; however, blinding will not be practical.
- Trial name
- NCT05354739
- Testing
- The vibration cold device (BUZZY)
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Low-Moderate Hypercholesterolemia
Clinical Trial to Demonstrate the Efficacy of a Dietary Supplement in Decreasing Cardiovascular Risk
This clinical trial seeks to verify the efficacy of a red rice yeast dietary supplement in the decrease of cardiovascular risk, by assessing variables related with cardiovascular risk as levels of cholesterol, triglycerides and…
- Trial name
- NCT03828006
- Testing
- Red Rice Yeast
- Where
- 3 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Bioksan
Myopia
Evaluation of the Efficacy in Decreasing Myopia Progression of the Proposed Ophthalmic Lens Prototypes
Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
- Trial name
- NCT05250206
- Testing
- Myopia control lens
- Where
- Spain
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Indizen Optical Technologies, S.L.U.
Hypertension, Left Ventricular Hypertrophy
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Overweight
- Trial name
- ALLAY (NCT00219141)
- Testing
- Aliskiren 150/300 mg, Losartan 50/100 mg
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Papillomavirus Infections
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
The present study is a multicenter, open, non-interventional, prospective observational clinical study for the evaluation of the effectiveness of Papilocare® (medical device with CE mark) in the regression of cervix cytological…
- Trial name
- PAPILOBSGR (NCT06399341)
- Testing
- Papilocare vaginal gel
- Where
- 4 sites in Greece
- Volunteers
- 524 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Hemodialysis Complication
UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.
The objective of this study was to verify the clinical non-inferiority of the pharmacodynamic effects and the safety of use of the drug Heptar® manufactured by Eurofarma Laboratory, compared to the drug Liquemine®, manufactured…
- Trial name
- HEPIRC (NCT05148377)
- Testing
- Liquaemin, Heptar
- Volunteers
- 128 people
- Sponsor
- Eurofarma Laboratorios S.A.
Hypertension; Hypertrophy, Left Ventricular
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
This study will evaluate the safety and efficacy of amlodipine plus valsartan in patients with hypertension and left ventricular hypertrophy
- Trial name
- NCT00446563
- Testing
- Valsartan, Amlodipine, Hydrochlorothiazide
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Novartis
Triglycerides High
Clinical Study to Evaluate the Blood Triglyceride Decreasing Effect and Safety of Korean Post-Fermented Tea Extracts
This study was conducted to investigate the effects of daily supplementation of Korean Post-Fermented Tea(Heukcha) Extracts on improvement of Blood Triglyceride Level.
- Trial name
- NCT04850352
- Testing
- Heukcha Extracts
- Where
- 3 sites in South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Amorepacific Corporation
Keloid
Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid
The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta and planned from June 2020 to December 2020.
- Trial name
- Keloid (NCT04326959)
- Testing
- Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium, Conditioned Medium, Triamcinolone Acetonide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PT. Prodia Stem Cell Indonesia
Neoplasms
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm.
- Trial name
- NCT03416335
- Testing
- DSP-0509, DSP-0509, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sumitomo Pharma America, Inc.
Treatment of Acne Vulgaris Grade II in a Short Period of Time.
Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)
Sixty two subjects will take part in this study. The study is unic arm. The subjects used the product once and will be evaluated in the regression of pimples in the times 0,4,6,8 and 24 hours after application.
- Trial name
- NCT01260571
- Testing
- Benzoyl peroxide and sulfur
- Where
- Brazil
- Volunteers
- 62 people
- Sponsor
- Zurita Laboratorio Farmaceutico Ltda.
Foot Pain, Foot Functionality
Orthotics, Pain & Fear of Falling
To investigate and compare the use of a prefabricated Orthotic, with and without a metatarsal pad in decreasing pain and fear of falling in older adults.
- Conditions
- Foot Pain, Foot Functionality, Fear of Falling
- Trial name
- NCT04894396
- Testing
- Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support, Aetrex L2300 Premium Memory Foam Orthotics
- Where
- United Kingdom
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Talita Cumi Ltd.
Atherosclerosis, Diabetes Mellitus
TART - Troglitazone Atherosclerosis Regression Trial
The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
- Trial name
- NCT00116545
- Testing
- troglitazone
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Parke-Davis
Plaque, Gingivitis
A Clinical Trial to Test the Effect of Marketed Mouth Rinses on Decreasing Plaque and Gum Inflammation
The reduction of existing plaque and gum inflammation will be evaluated using two marketed mouth rinses along with tooth brushing after 21 days of use compared to a placebo mouth rinse.
- Trial name
- NCT02233998
- Testing
- Mouth Rinse 1, Mouth Rinse 2, Mouth Rinse 3
- Where
- Canada
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02890069
- Testing
- PDR001, LCL161, Everolimus
- Where
- 25 sites in United States, Germany and 5 more
- Volunteers
- 298 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease Stage 3 and 4
Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)
Part 1: To determine the safety, tolerability, and pharmacokinetics of a single dose of 3 μg paricalcitol capsules in children ages 10 to 16 years with moderate to severe chronic kidney disease (CKD Stages 3 and 4).
- Trial name
- NCT01020487
- Testing
- Paricalcitol
- Volunteers
- 47 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Advanced Solid and Hematological TP53wt Tumors
Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.
- Trial name
- NCT02143635
- Testing
- HDM201, ancillary treatment
- Where
- 15 sites in United States, France and 6 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals